CER Daily Newsfeed

Podcast: The National Pharmaceutical Council President and CEO & Former Trump Drug Pricing Advisor, John O’Brien, PharmD, MPH

(1/8, Leerink: Perspectives Podcast) comments “Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, talks with John M. O’Brien, PharmD, MPH, President and CEO of the National Pharmaceutical Council & Former Trump Drug Pricing Advisor, to tackle some big questions like if it is possible to reward innovation without busting budgets and how to get to a sustainable, innovation-friendly, patient-centered drug pricing system.” Full

Ustekinumab Superior for Drug Survival to Other Psoriasis Biologics for Bio-Naïve

(1/8, Tim Smith, HCPLive) reports “...New findings suggest, among biologic-naïve (bio-naïve) patients living with psoriasis, ustekinumab has superior drug survival versus adalimumab and secukinumab. Among the bio-experienced, guselkumab, bimekizumab, and risankizumab had superior drug survival.” Full

House E&C Health Panel Weighs Bill To Bar CMS' WISeR Model

(1/8, Jalen Brown, Inside Health Policy) reports “...The renewed House pushback follows Senate Democrats’ introduction last month of legislation that would statutorily bar CMS from implementing WISeR, as well as a largely symbolic rebuke last year from House appropriators, who included language in an HHS spending bill seeking to block the model...‘While I understand the concerns around AI and prior authorization, CMMI’s statutory mission is to lower health care costs and improve outcomes for patients,’ [health subcommittee Chair Morgan Griffith (R-VA)] said. ‘The WISeR model does not change Medicare coverage policy but will focus on ensuring that for a set of non-emergency services, seniors are getting safe, effective and appropriate care.’” Subscription Required

From Early Detection to Targeted Therapy: How AI is Reframing Precision Medicine

(1/9, Andy Dé, MedCity News) comments “...In short, AI-enabled precision medicine offers a rare combination of better outcomes, better experiences, and better value. It brings us closer to a healthcare system that treats each individual as a cohort of one. The question now is how quickly we are willing to move toward that future.” Full

Where the 340B Rebates Pilot Stands Now, and What Comes Next

(1/9, Bridget Early, Modern Healthcare) reports “...The drugmakers AbbeVie, AstraZeneca, Boehringer Ingelheim and Novo Nordisk, which signed onto the rebates pilot, and the Pharmaceutical Research and Manufacturers of America petitioned the appeals court to allow them to intervene in the case after the district court rejected their request. ‘The rebate model is a commonsense approach to preventing unauthorized duplicate discounts and increasing overall program integrity,’ a PhRMA spokesperson wrote in an email.” Subscription Required

Connecting Real-World Datasets to Provide Deeper Insights into the Patient Journey

(1/9, The Evidence Base) reports “At ISPOR Europe 2025, Bruce Feinberg and Nicholas Lazarou of Cardinal Health assessed practical methods for improving real-world evidence through connected datasets. Their session explored data-integration challenges, the contribution of community networks, and how platforms such as SoNaR can enhance survival analyses and support more robust, regulatory-grade evidence.” Full